You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Preclinical evaluation of SERCA2 allosteric activators for pancreatic β-cell protection in diabetes.

    SBC: NEURODON, LLC            Topic: NIDDK

    The overall goal of this collaborative project between Neurodon and Indiana University School of Medicine is the development of compounds that will offer disease-modifying treatments for type 1 (T1D) and type 2 diabetes (T2D) mellitus, a sorely unmet need. In this initial STTR project, we will use our expertise in medicinal chemistry, cell biology, and diabetes pathophysiology to functionally test ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia

    SBC: FGF Therapeutics INC.            Topic: NIAMS

    Abstract Hyperphosphatemic familial tumoral calcinosis (hfTC) is a disease in which patients cannot produce the bioactive form of the hormone Fibroblast growth factor-23 (FGF23), which is secreted by osteocytes to rid the body of phosphate by acting on the kidney. hfTC is characterized by markedly elevated serum phosphate (Pi) which causes large intramuscular calcifications to develop. The calcifi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    In this Phase IIB SBIR project for Alzheimer’s disease (AD) drug development, Neurodon LLC proposes to conduct preclinical development and IND-enabling activities on our novel, orally available lead and backup compounds that, in our preceding Phase II project, showed neuroprotection and beneficial effects on learning and memory in a transgenic model of AD. Despite the enormity of AD as a nationa ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Injectable 3-month buprenorphine PLGA microparticle formulation

    SBC: AKINA, INC.            Topic: NIDA

    PROJECT SUMMARYThe objective of this Phase I study is to develop a 3-month delivery buprenorphine formulation for treating opioid use disorder (OUD). Developing a long-acting injectable buprenorphine formulation is urgently necessary for treating OUD. Currently, only two 1-month buprenorphine injectable formulations, Sublocade® and Brixadi®, are approved by the U.S. Food and Drug Administration ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

    SBC: OpalGenix, Inc.            Topic: NIDA

    PROJECT SUMMARY: Opioid Use Disorder (OUD) in pregnant women, Neonatal Opioid Withdrawal Syndrome (NOWS) and associated hospital costs have dramatically increased in the past decade, with an American child is born suffering from NOWS every 15 minutes. The ongoing opioid epidemic is further worsened by the COVID- 19 pandemic. Despite medication treatment for OUD with buprenorphine or methadone, the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Improving Analgesic Effectiveness and Safety with Proactive Precision Pain Management in Thoracic Surgical Patients with Lung Lesions

    SBC: OpalGenix, Inc.            Topic: NHLBI

    PROJECT SUMMARY Thoracic surgery (TS), especially pneumonectomy, lobectomy and segmentectomy, are common and very painful surgeries for lung lesions with high incidence of uncontrolled acute surgical pain, chronic post- thoracotomy pain and excessive opioid use. Those with poorly controlled acute surgical pain are at risk for chronic post-surgical pain (CPSP), long-term opioid use and opioid addic ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Optical gearbox enabled high-speed multiphoton microscope

    SBC: PHOTOMATRIX            Topic: 101

    ABSTRACT Neurological disorders affect millions of people each year, many with no cures. Researchers and clinicians are actively seeking a deeper understanding of how the human brain functions to develop new treatments and cures. Optical functional imaging is a tool broadly applied in neuroscience. The advance of genetically encoded functional indicators allows the visualization of neuronal activi ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Translational Assays for Inflammatory Biomarkers for the Risk Stratification of Pancreatic Cystic Lesions

    SBC: Amplified Sciences, LLC            Topic: NCI

    PROJECT SUMMARY Advances in clinical imaging technologies have increased the incidental detection rate of cystic pancreatic lesions. However, patients remain at risk due to the lack of a definitive diagnosis that accurately assesses if these cysts are pre-malignant. In the absence of robust diagnostic indicators, clinicians must balance patient safety due to a cystic lesion's rapid and aggressive ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. All-in-one Device for Forensic Toxicology Drug Screening

    SBC: WIK DEVICES LLC            Topic: NIDA

    Project Summary/AbstractDrug screening in toxicology cases is performed mainly using immunoassays, gas- chromatography mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS). Immunoassays lack the sensitivity, multiplexing capability, and flexibility to respond to the rise of potent synthetic drugs including fentanyl analogs and synthetic cannabinoids. GC- MS requires exten ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Coccidioides Cytokine Release Assay

    SBC: MIRAVISTA DIAGNOSTICS LLC            Topic: NIAID

    Coccidioidomycosis (CM) is an endemic mycosis caused by the fungi Coccidioides immitis and Coccidioides posadasii, which is native to arid regions of North and South America. It is estimated that up to 350,000 infections occur annually in the U.S. Additionally, up to a third of community acquired pneumonia cases in these areas are thought to be a result of CM. Morbidity associated with CM is subst ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government